You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和譽-B(02256.HK)在2024年ACoP會議展示匹米替尼模型引導的劑量選擇研究結果
格隆匯 11-13 07:02

格隆匯11月13日丨和譽-B(02256.HK)發佈公吿,公司的附屬公司上海和譽生物醫藥科技有限公司(“和譽醫藥”)在2024年美國定量藥理學大會(“2024年ACoP會議”)上展示了其自主研發的口服、高選擇性、活性CSF-1R小分子抑制劑匹米替尼 (ABSK021)治療腱鞘鉅細胞瘤(“TGCT”)的模型引導的劑量選擇研究結果。此次發佈的研究綜合藥物代謝動力學、安全性和有效性信息,用於指導模型引導劑量的選擇。研究結果支持50mg QD作為匹米替尼在全球開發和治療TGCT的推薦劑量。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account